MedTrace Logo

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

NCT00877474 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-11-04

No results posted yet for this study

Summary

This is a phase I, multicenter, open-label, dose escalating clinical and pharmacokinetic study of PM01183 for patients with advanced solid tumors

Conditions

Interventions

DRUG

PM01183

Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion

Sponsors & Collaborators

  • PharmaMar

    lead INDUSTRY

Principal Investigators

  • Mark Ratain, MD · Cancer Research Center. University of Chicago Hospitals.

  • Josep Tabernero, MD · Vall d'Hebron University Hospital. Barcelona (Spain)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00877474 on ClinicalTrials.gov